SEC Form S-8 filed by Entera Bio Ltd.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
———————————
Entera Bio Ltd.
(Exact name of registrant as specified in its charter)
State of Israel
|
Not Applicable
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
Kiryat Hadassah
Minrav Building – Fifth Floor
Jerusalem, Israel
(Address of Principal Executive Offices)
|
9112002
(Zip Code)
|
Large accelerated filer
|
☐
|
Accelerated filer
|
☐
|
|
Non-accelerated filer
|
☒
|
Smaller reporting company
|
☒
|
|
Emerging growth company
|
☐
|
Item 3. |
Incorporation of Documents by Reference.
|
(a) |
The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Commission on March 8,
2024, pursuant to Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”);
|
(b) |
The Registrant’s Quarterly Reports on Form 10-Q for the quarter ended March 31, 2024, filed with the Commission on May 10, 2024
and for the quarter ended June 30, 2024, filed with the Commission on August 9, 2024;
|
(c) |
The Registrant’s Current Reports on Form 8-K filed with the Commission on January 3, 2024 and August 2, 2024; and
|
(d) |
The Registrant’s Registration Statement on Form 8-A filed with the Commission on June 25, 2018 (File No. 001-38556), in which
there is described the terms, rights and provisions applicable to the Ordinary Shares, including any amendment or report filed for the purpose of updating such description, including the description of the Ordinary Shares filed as Exhibit 2.2 to the Registrant’s Annual Report on Form 20-F filed with the Commission on March 18, 2021.
|
Additionally, all documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (not including any information furnished under Items 2.02, 7.01 or 9.01 of Form 8-K, which information is not incorporated by reference herein), prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold shall be deemed to be incorporated herein by reference and to be a part of the Registration Statement from the date of filing of such documents. Any statement contained in a document incorporated herein by reference will be deemed to be modified or superseded for purposes of the Registration Statement to the extent that a statement contained herein, or in a subsequently filed document incorporated herein by reference, modifies or supersedes the statement. Any statement modified or superseded will not be deemed, except as modified or superseded, to constitute a part of the Registration Statement.
Exhibit No.
|
Description
|
|
ENTERA BIO LTD.
|
|||
By:
|
/s/ Miranda Toledano |
||
Name: | Miranda Toledano | ||
Title: | Chief Executive Officer |
Signature
|
Title
|
Date
|
||
/s/ Miranda Toledano
|
Chief Executive Officer and Director
(Principal Executive Officer)
|
August 9, 2024
|
||
Miranda Toledano
|
||||
/s/ Dana Yaacov-Garbeli
|
Chief Financial Officer
(Principal Financial and Accounting Officer)
|
August 9, 2024
|
||
Dana Yaacov-Garbeli
|
||||
/s/ Gerald Lieberman
|
Chairman of the Board
|
August 9, 2024
|
||
Gerald Lieberman
|
||||
/s/ Yonatan Malca
|
Director
|
August 9, 2024
|
||
Yonatan Malca
|
||||
/s/ Sean Ellis
|
Director
|
August 9, 2024
|
||
Sean Ellis
|
||||
/s/ Haya Taitel
|
Director
|
August 9, 2024
|
||
Haya Taitel
|
||||
/s/ Gerald M. Ostrov
|
Director
|
August 9, 2024
|
||
Gerald M. Ostrov
|